The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: Insight from Danish nationwide registers

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients : Insight from Danish nationwide registers. / Ruwald, Anne Christine; Gislason, Gunnar Hilmar; Vinther, Michael; Johansen, Jens Brock; Nielsen, Jens Cosedis; Petersen, Helen Høgh; Torp-Pedersen, Christian; Riahi, Sam; Jøns, Christian.

I: Europace, Bind 20, Nr. 2, 2018, s. 301-307.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Ruwald, AC, Gislason, GH, Vinther, M, Johansen, JB, Nielsen, JC, Petersen, HH, Torp-Pedersen, C, Riahi, S & Jøns, C 2018, 'The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: Insight from Danish nationwide registers', Europace, bind 20, nr. 2, s. 301-307. https://doi.org/10.1093/europace/euw408

APA

Ruwald, A. C., Gislason, G. H., Vinther, M., Johansen, J. B., Nielsen, J. C., Petersen, H. H., Torp-Pedersen, C., Riahi, S., & Jøns, C. (2018). The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: Insight from Danish nationwide registers. Europace, 20(2), 301-307. https://doi.org/10.1093/europace/euw408

Vancouver

Ruwald AC, Gislason GH, Vinther M, Johansen JB, Nielsen JC, Petersen HH o.a. The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: Insight from Danish nationwide registers. Europace. 2018;20(2):301-307. https://doi.org/10.1093/europace/euw408

Author

Ruwald, Anne Christine ; Gislason, Gunnar Hilmar ; Vinther, Michael ; Johansen, Jens Brock ; Nielsen, Jens Cosedis ; Petersen, Helen Høgh ; Torp-Pedersen, Christian ; Riahi, Sam ; Jøns, Christian. / The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients : Insight from Danish nationwide registers. I: Europace. 2018 ; Bind 20, Nr. 2. s. 301-307.

Bibtex

@article{8a79297912584049b3ebc3533d538632,
title = "The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: Insight from Danish nationwide registers",
abstract = "Aims We aimed to examine the use of guideline recommended beta-blocker therapy prior to and after primary prevention implantable cardioverter defibrillator (ICD) implantation in a {\^a} real-life' setting. Methods and results From the Danish Pacemaker and ICD Registry we identified all 1st-time primary prevention ICD and cardiac resynchronization therapy defibrillator (CRT-D) implantations in Denmark from 2007-12 (n = 2935). Use of beta-blocker, type and dose was acquired through the Danish Prescription Registry. According to guideline recommendations, we defined target daily doses as ≥50 mg carvedilol and ≥200 mg metoprolol. Prior to implantation 2427 of 2935 (83%) patients received beta-blocker therapy, with 2166 patients (89%) having initiated treatment 3 months or more prior to implantation. The majority of patients was prescribed carvedilol (52%) or metoprolol (41%). Patients on carvedilol reached target dosages more frequently than patients on metoprolol, with 39% of patients on carvedilol and 26% of patients on metoprolol at the time of implantation (P < 0.001 for all time-points). Increase in proportion of patients reaching target daily doses was observed for both carvedilol and metoprolol after ICD implantation. Carvedilol treatment was a strong predictor for being on target dose of BB at time of implant, as was treatment with angiotensin-converting enzyme inhibitors and/or spironolactone, no history of myocardial infarction, younger age and less pronounced heart failure symptoms Conclusion In a real-life setting of primary prevention ICD patients, 39% and 26% of patients were titrated to optimal target dose of carvedilol or metoprolol prior to implantation. A higher proportion of patients on carvedilol reached target dose, as compared with metoprolol.",
keywords = "Carvedilol, Heart failure, Metoprolol, Predictors, Target dose, Treatment",
author = "Ruwald, {Anne Christine} and Gislason, {Gunnar Hilmar} and Michael Vinther and Johansen, {Jens Brock} and Nielsen, {Jens Cosedis} and Petersen, {Helen H{\o}gh} and Christian Torp-Pedersen and Sam Riahi and Christian J{\o}ns",
year = "2018",
doi = "10.1093/europace/euw408",
language = "English",
volume = "20",
pages = "301--307",
journal = "Europace",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "2",

}

RIS

TY - JOUR

T1 - The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients

T2 - Insight from Danish nationwide registers

AU - Ruwald, Anne Christine

AU - Gislason, Gunnar Hilmar

AU - Vinther, Michael

AU - Johansen, Jens Brock

AU - Nielsen, Jens Cosedis

AU - Petersen, Helen Høgh

AU - Torp-Pedersen, Christian

AU - Riahi, Sam

AU - Jøns, Christian

PY - 2018

Y1 - 2018

N2 - Aims We aimed to examine the use of guideline recommended beta-blocker therapy prior to and after primary prevention implantable cardioverter defibrillator (ICD) implantation in a â real-life' setting. Methods and results From the Danish Pacemaker and ICD Registry we identified all 1st-time primary prevention ICD and cardiac resynchronization therapy defibrillator (CRT-D) implantations in Denmark from 2007-12 (n = 2935). Use of beta-blocker, type and dose was acquired through the Danish Prescription Registry. According to guideline recommendations, we defined target daily doses as ≥50 mg carvedilol and ≥200 mg metoprolol. Prior to implantation 2427 of 2935 (83%) patients received beta-blocker therapy, with 2166 patients (89%) having initiated treatment 3 months or more prior to implantation. The majority of patients was prescribed carvedilol (52%) or metoprolol (41%). Patients on carvedilol reached target dosages more frequently than patients on metoprolol, with 39% of patients on carvedilol and 26% of patients on metoprolol at the time of implantation (P < 0.001 for all time-points). Increase in proportion of patients reaching target daily doses was observed for both carvedilol and metoprolol after ICD implantation. Carvedilol treatment was a strong predictor for being on target dose of BB at time of implant, as was treatment with angiotensin-converting enzyme inhibitors and/or spironolactone, no history of myocardial infarction, younger age and less pronounced heart failure symptoms Conclusion In a real-life setting of primary prevention ICD patients, 39% and 26% of patients were titrated to optimal target dose of carvedilol or metoprolol prior to implantation. A higher proportion of patients on carvedilol reached target dose, as compared with metoprolol.

AB - Aims We aimed to examine the use of guideline recommended beta-blocker therapy prior to and after primary prevention implantable cardioverter defibrillator (ICD) implantation in a â real-life' setting. Methods and results From the Danish Pacemaker and ICD Registry we identified all 1st-time primary prevention ICD and cardiac resynchronization therapy defibrillator (CRT-D) implantations in Denmark from 2007-12 (n = 2935). Use of beta-blocker, type and dose was acquired through the Danish Prescription Registry. According to guideline recommendations, we defined target daily doses as ≥50 mg carvedilol and ≥200 mg metoprolol. Prior to implantation 2427 of 2935 (83%) patients received beta-blocker therapy, with 2166 patients (89%) having initiated treatment 3 months or more prior to implantation. The majority of patients was prescribed carvedilol (52%) or metoprolol (41%). Patients on carvedilol reached target dosages more frequently than patients on metoprolol, with 39% of patients on carvedilol and 26% of patients on metoprolol at the time of implantation (P < 0.001 for all time-points). Increase in proportion of patients reaching target daily doses was observed for both carvedilol and metoprolol after ICD implantation. Carvedilol treatment was a strong predictor for being on target dose of BB at time of implant, as was treatment with angiotensin-converting enzyme inhibitors and/or spironolactone, no history of myocardial infarction, younger age and less pronounced heart failure symptoms Conclusion In a real-life setting of primary prevention ICD patients, 39% and 26% of patients were titrated to optimal target dose of carvedilol or metoprolol prior to implantation. A higher proportion of patients on carvedilol reached target dose, as compared with metoprolol.

KW - Carvedilol

KW - Heart failure

KW - Metoprolol

KW - Predictors

KW - Target dose

KW - Treatment

U2 - 10.1093/europace/euw408

DO - 10.1093/europace/euw408

M3 - Journal article

C2 - 28339659

AN - SCOPUS:85041692314

VL - 20

SP - 301

EP - 307

JO - Europace

JF - Europace

SN - 1099-5129

IS - 2

ER -

ID: 213964266